The detectability of psilocybin, the psychoactive compound in certain fungi, through standard drug screening methods is limited. Common drug tests are not designed to identify psilocybin or its metabolite, psilocin. For example, a standard 5-panel or 10-panel drug test typically screens for substances like amphetamines, cocaine, opiates, phencyclidine (PCP), and tetrahydrocannabinol (THC), but not psilocybin.
The relative impermanence of psilocybin in the body contributes to the difficulty in detecting it. The compound is metabolized relatively quickly, and traces remain detectable for a short period compared to other substances. While historical use and societal perception have led to categorization alongside other controlled substances, the lack of specific and widespread testing protocols means that targeted screening is rare. This infrequency of testing stems from factors including cost, technological limitations, and the relatively lower perceived risk compared to commonly abused substances.